Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT07053254
Recruiting Observational

The Characteristics and Treatment Mechanism of Vascular Grafts in Elderly Patients With CAOD Through Single-cell Transcriptome Analysis

NCT07053254 · tracked via the Priya Life Science South Korea tracker
Sponsor
Yonsei University
Phase
Observational
Started
2022-04-12
Last updated
2025-07-08

Condition(s) studied

Coronary Artery Occlusive Disease (CAOD)

Study summary

This study aims to establish a cardiovascular biobank using vascular grafts obtained from participants with coronary artery occlusive disease (CAOD). Through genomic and transcriptomic analyses, the study seeks to characterize the biological features of the vascular grafts and identify potential therapeutic targets and mechanisms related to vascular remodeling and stiffness.

Eligibility

Sex
ALL
Min age
19 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 19 years or older, Patients scheduled to undergo coronary artery bypass grafting (CABG), Patients who voluntarily provide written informed consent for study participation, Patients who are able and willing to comply with study procedures during the study period Exclusion Criteria: * Pediatric or adolescent patients under 18 years of age, Patients requiring concomitant surgical correction for valvular heart disease, Patients undergoing reoperative (redo) cardiac surgery, Patients who decline to provide informed consent prior to surgery

Primary outcome measure(s)

  • Identification of gene expression profiles associated with vascular stiffness in graft tissues — At the time of surgery (single timepoint sample collection)
    To identify differentially expressed genes and signaling pathways related to vascular stiffness using total RNA sequencing of vascular graft tissues obtained during coronary artery bypass grafting (CABG).

Trial sites (1)

FacilityCityRegionStatus
Division of Cardiovascular Surgery, Severance Cardiovascular Hospital , Yonsei University College of Medicine Seoul South Korea Recruiting

More Yonsei University trials in South Korea

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC Recruiting
Aspirin vs Clopidogrel After TAVR Recruiting
Clinical Effectiveness of a Motivational Interviewing-Based Conversational Mobile Application for High-Risk Drinkers Recruiting
Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) Recruiting
Home-based Rehabilitation Monitoring System With Wearable Devices and Self-Report Application Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07053254 on ClinicalTrials.gov ↗ ← All trials in South Korea